foslevodopa/foscarbidopa vs TR-012001

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

foslevodopa/foscarbidopa · Vyalev

Marketed by AbbVie

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT04380142 · Phase 3 · completed

The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).

Reported efficacy

Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5) (met)

Result source: NCT04380142

TR-012001

Developed by SNLD, Ltd.

Phase 2 in Parkinson's Diseasesmall molecule
Weak signal

NCT06212089 · Phase 2 · completed

The study randomly assigned 12 Japanese patients with Parkinson's disease to one nasal dose of TR-012001 or placebo, single-blind. Its registered primary outcomes were safety measures, so there is no efficacy comparison to call. The AAN 2025 abstract reports that all adverse drug reactions were mild, transient nasal reactions and that 8 of 9 treated patients reached peak plasma levodopa within 15 minutes. The study is very small and tested a single dose.

Conference abstract (AAN 2025); not peer reviewed and not posted on ClinicalTrials.gov.

Reported efficacy

Safety evaluation of TR-012001: Incidents of Treatment-Emergent Adverse Events (Day of administration of TR-012001/placebo (Day3) to the day of leaving the facility (Day4). If any adverse event(s) continue or occur on Day4, follow-up will be conducted until recovery or until the investigator decides no longer follow-up is necessary.); Safety evaluation of TR-012001: Incidents of physical findings (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (body temperature) (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (blood pressure) (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (pulse rate) (4 days and 3 nights); Safety evaluation of TR-012001: Columbia Suicide Severity Rating Scale (C-SSRS) (Day 1 and Day 4); Safety evaluation of TR-012001: Incidents of participants with laboratory abnormality (Day 1 and Day 4); Pharmacokinetics of TR-012001: Maximum plasma concentration (Cmax) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Time to reach maximum plasma concentration (Tmax) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Elimination half-life (t1/2) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Area under the plasma concentration-time curve (AUC0-inf) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Mean residence time (MRT) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Apparent whole body clearance (CL/f) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Volume of distribution (Vd/f ) (Pre-dose (baseline) and specified time points of post-dose): Single nasal dose in 12 patients (9 TR-012001, total levodopa 40 mg; 3 placebo): all adverse drug reactions were mild and transient nasal administration reactions, and all 12 patients completed. 8 of 9 TR-012001 patients reached peak plasma levodopa within 15 minutes of dosing. (not_applicable)

Result source: NCT06212089

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfoslevodopa/​foscarbidopaTR-012001
OFF time, change-2.8 vs -1.0vs LD/CDwk 12 · n 47NCT04380142—Not reported
ON time without troublesome dyskinesia, change2.7 vs 1.0vs LD/CDwk 12 · n 47NCT04380142—Not reported
UPDRS Part III, change—Not posted · NCT04379050—Not reported
MDS-UPDRS Part II, change-2.6 vs -1.1vs LD/CDwk 12 · n 46NCT04380142—Not reported

OFF time, change

foslevodopa/​foscarbidopa
-2.8 vs -1.0vs LD/CDwk 12 · n 47NCT04380142
TR-012001
—Not reported

ON time without troublesome dyskinesia, change

foslevodopa/​foscarbidopa
2.7 vs 1.0vs LD/CDwk 12 · n 47NCT04380142
TR-012001
—Not reported

UPDRS Part III, change

foslevodopa/​foscarbidopa
—Not posted · NCT04379050
TR-012001
—Not reported

MDS-UPDRS Part II, change

foslevodopa/​foscarbidopa
-2.6 vs -1.1vs LD/CDwk 12 · n 46NCT04380142
TR-012001
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

TR-012001: no structured comparison results are available for Parkinson's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. foslevodopa/foscarbidopa: 4 of 4 rows · TR-012001: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfoslevodopa/​foscarbidopa
Dropout rate
—
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
—ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
42.5%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
35.9%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Discontinued due to AEs
—
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
—ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
22.1%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
17.6%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Serious AEs
8.1%
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
25.8%ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
27.4%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
24.4%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Most frequent reported AEs
infusion site erythema 27%
infusion site pain 25.7%
infusion site cellulitis 17.6%
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
infusion site erythema 52%
infusion site nodule 28.7%
infusion site oedema 19.3%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
high dose
infusion site erythema 55.8%
infusion site nodule 30.1%
infusion site oedema 24.8%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
low dose
infusion site erythema 48.9%
infusion site nodule 27.5%
infusion site cellulitis 19.1%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

foslevodopa/foscarbidopa

On" Time Without Troublesome Dyskinesia 2.72 vs 0.97 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
OFF Time -2.75 vs -0.96 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
MDS-UPDRS Part II -2.65 vs -1.06 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
Early Morning "Off 17% (n=47) vs 63.3% (n=60) LD/CD @ 12wk
responder rate · % of participants
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
ON Time Without Dyskinesia 3.13 vs 1.32 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
PDSS-2 Total -7.92 vs -2.52 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
PDQ-39 Summary Index -6.38 vs -2.28 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
EQ-5D-5L Summary Index 0.051 vs 0.002 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
OFF Time -2.04 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
-1.84 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.95 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.43 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.36 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.4 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.5 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.34 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.43 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.31 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.38 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.35 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.25 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.52 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.37 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.43 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.59 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.51 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Daily on Time With Troublesome Dyskinesia 0 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
0.11 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.05 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.56 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.23 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.41 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.6 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.38 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.5 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.61 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.27 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.45 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.49 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.17 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.35 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.64 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.17 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.27 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Daily on Time Without Troublesome Dyskinesia 2.04 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
1.74 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.9 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.99 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.6 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.81 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.1 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.72 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.93 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.92 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.65 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.79 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.74 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.69 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.71 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
4.08 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.43 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.77 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part I -2.6 score @ 0.29wklow dose
absolute change · score
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 29 more results
-1.8 score @ 0.29wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 0.29wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 1wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.9 score @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.5 score @ 2wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.1 score @ 2wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 2wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 3wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.9 score @ 3wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 3wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 4wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3 score @ 4wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 4wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.1 score @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.4 score @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.8 score @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.1 score @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.9 score @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.1 score @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.4 score @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.5 score @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.3 score @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.9 score @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: foslevodopa/foscarbidopa's landscape · TR-012001's landscape